Zoetis Inc (ZTS)
Zoetis Inc (ZTS) carries a ŷRobot AI score of 66 out of 100. The model's fair value estimate is $88.12, 5.1% above the last close of $83.82. The chart signal reads Sell.
| Metric | ZTS |
|---|---|
| AI score | 66 / 100 |
| Chart signal | Sell |
| Fair value estimate | $88.12 |
| Upside to fair value | 5.1% |
| Previous close | $83.82 |
| P/E | 13.66 |
| Price / sales | 3.56 |
| Market cap | $33.71B |
| EPS | 6.53 |
| Revenue growth | 5.5% |
| 1-year price change | 2.4% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about ZTS
Is ZTS overvalued or undervalued right now?
As of Nov 6, 2026, ŷRobot's fair-value model estimates Zoetis Inc (ZTS) at $88.12 against a last close of $83.82, implying 5.1% upside to the model's estimate.
Is ZTS's chart signal bullish or bearish?
The chart-signal model classifies ZTS as Neutral as of Nov 14, 2026, with a signal score of -0.12 on a -1 to 1 scale.
What is ZTS's ŷRobot AI score?
ZTS scores 66 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 14, 2026.
Is ZTS stock expensive on P/E and P/S?
ZTS trades at 13.7 times earnings and 3.6 times sales as of Nov 14, 2026.
What does ZTS's seasonal forecast show?
ŷRobot's seasonal forecast curve for ZTS reads +1.8% at 30 days, +3.3% at 90 days, and +2.4% at one year as of Nov 14, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is ZTS growing?
Zoetis Inc's revenue growth is +5.5% and free-cash-flow growth is +6.9% on the latest reported figures.
ZTS chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.